Article
Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.
Neurology - 26 Jul 2005
Moonis M, Swearer J M, Dayaw M P E, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen D A
Abstract excerpt
CSF amyloid beta-peptide 42 (Abeta42) levels in presymptomatic subjects with pathogenic mutations in the PS1 gene are significantly lower than in an age-matched control group. Consequently, in these subjects, there is a window of opportunity estimated as at least 4 to 12 years to evaluate the ability of any putative prophylactic therapy to decrease, arrest, or reverse abnormalities in Abeta42 metabolism many...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.